Jinghua Pharmaceutical Group Co., Ltd. Share Price

Equities

002349

CNE100000L14

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 25/04/2024 BST 5-day change 1st Jan Change
7.76 CNY +0.65% Intraday chart for Jinghua Pharmaceutical Group Co., Ltd. +3.33% -12.51%

Financials

Sales 2022 1.57B 217M 17.39B Sales 2023 1.51B 209M 16.71B Capitalization 7.22B 997M 79.81B
Net income 2022 212M 29.26M 2.34B Net income 2023 248M 34.23M 2.74B EV / Sales 2022 5.59 x
Net cash position 2022 1.04B 143M 11.45B Net cash position 2023 1.22B 168M 13.45B EV / Sales 2023 3.97 x
P/E ratio 2022
46.3 x
P/E ratio 2023
29.2 x
Employees 1,641
Yield 2022
0.66%
Yield 2023
-
Free-Float 59.32%
More Fundamentals * Assessed data
Dynamic Chart
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jinghua Pharmaceutical's Unit Shuts Down Amid Water Pollution Probe MT
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jinghua Pharmaceutical Group Co., Ltd. Announces Cash Dividend for 2022, Payable on 9 June 2023 CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Jinghua Pharmaceutical Group Co., Ltd. Proposes Final Dividend for the Year 2022 CI
Jinghua Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2022 CI
Jinghua Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2022 CI
China COVID infection fears fuel medical stock bets RE
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Jinghua Pharmaceutical Group Co., Ltd.(XSEC:002349) added to S&P Global BMI Index CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Jinghua Pharmaceutical Group Co., Ltd. Implements 2021 Final Profit Distribution Plan (A Shares), Payable on 13 June 2022 CI
Jinghua Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
More news
1 day+0.65%
1 week+3.33%
Current month-1.77%
1 month-0.13%
3 months+0.13%
6 months-13.10%
Current year-12.51%
More quotes
1 week
7.46
Extreme 7.46
7.79
1 month
7.10
Extreme 7.1
8.11
Current year
5.88
Extreme 5.88
9.13
1 year
5.88
Extreme 5.88
11.00
3 years
4.43
Extreme 4.43
28.80
5 years
3.96
Extreme 3.96
28.80
10 years
3.46
Extreme 3.4567
30.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 17/11/13
Director of Finance/CFO 55 07/02/21
Chief Operating Officer 50 27/08/17
Members of the board TitleAgeSince
Chief Executive Officer 60 17/11/13
Director/Board Member 63 12/11/19
Chairman 58 02/03/17
More insiders
Date Price Change Volume
26/04/24 7.76 +0.65% 9,837,583
25/04/24 7.71 +0.52% 8,823,200
24/04/24 7.67 +0.52% 6,327,425
23/04/24 7.63 +0.26% 7,047,000
22/04/24 7.61 +1.33% 9,460,441

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes
JINGHUA PHARMACEUTICAL GROUP CO., LTD., formerly NANTONG JINGHUA PHARMACEUTICAL CO., LTD., is a China-based company, principally engaged in the research and development, production and distribution of Chinese patent drugs, pharm ingredients and intermediates and chemical intermediates. The Company is also engaged in the provision of traditional Chinese medicinal materials and Chinese herbal pieces, among others. The Company primarily provides tablets, capsules, pills, granules, injections, powder, syrup, healthcare products, beverages and chemical intermediates, among others. The Company offers Chinese patent medicines, such as Wangshi Baochiwan pills and Jidesheng tablets. Its bulk drugs include phenobarbitone and fluorouracil. The Company distributes its products in domestic and overseas markets.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 002349 Stock